1 December 2021 in JCO Global Oncology
PURPOSE: In Tanzania, cancer of cervix is the most commonly diagnosed cancer and is the leading cause of cancer-related deaths. There are very little data about survival of patients with cervical cancer after treatment in Tanzania. The aims of this study were to determine 5-year overall survival (OS) rate and its predictors among patients with cervical cancer treated at Ocean Road Cancer Institute (ORCI) from January to December 2012. MATERIALS AND METHODS: This was retrospective study done at ORCI by reviewing medical charts of 202 patients with cervical cancer treated at ORCI from January to December 2012. A structured questionnaire was used to extract information about characteristics of the respondents. Survival curves were estimated by using Kaplan-Meir analysis and were compared by using log-rank test. RESULTS: The 5-year OS rate was 26%. The mean and median survival times were 33.9 and 19 months, respectively. Factors that were positively associated with 5-year OS rate include the hemoglobin level more than 9 g/dL at presentation, early International Federation of Gynecology and Obstetrics stage at presentation, high dose of radiotherapy, and use of concurrent chemoradiotherapy. Histology type and HIV status were not associated with survival. CONCLUSION: The 5-year overall survival rate was 26%. Predictors of OS were hemoglobin level, stage at presentation, radiotherapy dose, and the use of concurrent chemoradiotherapy.
1 September 2023 in JCO Global Oncology
PURPOSE: Cervical cancer (CC) is the leading malignancy in Tanzania. Low-income countries are faced with double epidemics of HIV and CC. This study aimed to investigate how HIV and cancer stage at diagnosis affect early treatment outcomes among women with CC treated with concurrent chemoradiation in Tanzania in the highly active antiretroviral therapy era. MATERIALS AND METHODS: This was a prospective cohort study of patients newly diagnosed with CC at the Ocean Road Cancer Institute from November 2019 to January 2020. The tumor response was assessed using RECIST 3 months post-treatment. The tumor response was categorized as a complete or partial response according to the ultrasound and pelvic examination findings. The univariate and multivariate logistic regression explained the relationship between several covariates (age, stage, HIV status, equivalent dose in 2 Gy fractions, chemotherapy cycles, and treatment time) and treatment response. RESULTS: A total of 102 patients with CC were included in this study at baseline. After adjusting for other covariates, only completion of treatment within 56 days (odds ratio [OR], 9.23; 95% CI, 1.53 to 55.85; P = .016) and receiving at least three cycles of cisplatin (OR, 5.6; 95% CI, 1.47 to 21.34; P = .012) were significantly associated with complete tumor response. HIV status was not significantly associated with complete tumor response (OR, 1.534; 95% CI, 0.424 to 5.545; P = .5144). CONCLUSION: Early treatment response was independent of HIV status. With wide coverage of anitretroviral therapy, patients with HIV can receive radical treatment and have the same early outcomes as their HIV-negative counterparts.
1 January 2024 in Case Reports in Obstetrics and Gynecology
Background: Metastatic vulvar choriocarcinoma, a rare ectopic gestational trophoblastic neoplasia (GTN), often presents a diagnostic challenge due to its mimicry of other conditions, particularly in resource‐limited settings. Its primary symptom is abnormal vaginal bleeding without a clear cause. Consequently, diagnosing and managing it poses difficulties for many low‐resource health facilities, as evidenced by the current case.Case Presentation: We present the case of a 25‐year‐old, P2+2+2L2, who had a large painless, bleeding vulva mass for nearly 5 months. This followed a spontaneous abortion the month prior. The mass gradually increased in size and was accompanied by fever, pus discharge, and weight loss. Despite being treated at multiple health facilities for a vulvar abscess, there was no improvement. A diagnosis was finally made at a tertiary facility where elevated quantitative serum beta‐human chorionic gonadotropin (hCG) (β‐hCG) was noted. Due to uncontrollable vulva bleeding, she was referred to another tertiary facility for emergency radiotherapy. Following stabilization, chemotherapy was administered using the EMA‐CO protocol.Conclusion: The report highlights the difficulty in diagnosing vulvar choriocarcinoma, underscoring the importance of a high index of suspicion. Clinical tests such as serum (β‐hCG) and imaging studies are crucial for diagnosis. In resource‐limited settings, a simple strip‐based urine pregnancy test with serial dilutions can be sufficient for diagnosing and managing vulvar choriocarcinoma.
1 January 2026 in Case Reports in Oncological Medicine
Introduction: Persistent fever in patients with cancer presents a significant diagnostic challenge, particularly in settings where infectious diseases are highly prevalent. Neoplastic fever is an important noninfectious cause of fever that may mimic infection and result in unnecessary investigations, antimicrobial therapy, and delays in cancer treatment. Case Presentation: We report a case of a 45‐year‐old female patient with advanced cervical carcinoma who presented with persistent high‐grade fever unresponsive to antibiotics. An extensive infectious workup was negative. Following exclusion of alternative causes, a naproxen challenge was performed, resulting in rapid resolution of fever within 24 h. Fever recurred upon withdrawal and resolved again after naproxen reintroduction, supporting the diagnosis of neoplastic fever. Conclusion: Neoplastic fever should be considered early in cancer patients with persistent unexplained fever, particularly in tuberculosis‐ and malaria‐endemic settings. Following exclusion of infection, the naproxen challenge may provide a simple and affordable diagnostic step to distinguish neoplastic fever from infectious causes, reduce unnecessary antimicrobial use, shorten diagnostic delays, and facilitate timely cancer‐directed therapy.
30 September 2026 in Tanzania Medical Journal
JKJesse Jonathan Kashabano
Background: Laryngeal cancer (LC) represents the most common head and neck squamous cell carcinoma in Tanzania. Although global trends demonstrate declining incidence and improving outcomes, survival disparities remain substantial, largely driven by inequities in access to definitive surgical care and the increasing adoption of organ preservation strategies. In low- and middle-income countries, delayed presentation and limited access to multimodal treatment continue to affect outcomes adversely. This study aimed to identify factors associated with 5-year overall survival (OS) among patients with LC managed at a tertiary cancer center in Dar es Salaam, Tanzania, within the context of organ–preservation–based therapy. Methods: A retrospective cohort study was conducted at the Ocean Road Cancer Institute (ORCI). Medical records of 82 patients diagnosed with LC and treated between 2008 and 2012 were reviewed. The primary outcome was 5-year OS. Survival probabilities were estimated using the Kaplan–Meier method. The log-rank test was used for univariate comparisons, and multivariate analysis was performed using Cox proportional hazards regression. Results: Laryngeal squamous cell carcinoma accounted for 99% of cases and predominantly affected males (male-to-female ratio 10:1), with a mean age of 61 years. Hoarseness was the most common presenting symptom (90.2%). Most patients (72.3%) presented with advanced disease (stage III–IV). The 5-year overall survival was 29%. In multivariable Cox proportional hazards analysis, supraglottic tumor location remained independently associated with worse overall survival compared with glottic tumors (adjusted HR [aHR] 2.13, 95% CI 1.16–3.91, p = 0.015). Treatment-related factors were independently associated with improved survival, including receipt of an EQD2 dose ≥46 Gy (aHR 0.50, 95% CI 0.26–0.97, p = 0.041) and CCRT (aHR 0.46, 95% CI 0.23–0.92, p = 0.029. Conclusion: The 5-year OS was 29%. Poor survival was independently associated with supraglottic tumor location, absence of concurrent chemotherapy, and lower total RT dose. These findings underscore the importance of optimizing definitive treatment in this setting, particularly through appropriate RT dose escalation and broader use of concurrent chemoradiotherapy. Where feasible, carefully selected patients may also benefit from timely salvage laryngectomy within an organ preservation framework to improve long-term disease control.
1 October 2026 in JCO Global Oncology
Purpose: The National Comprehensive Cancer Network (NCCN) Harmonized Guidelines for sub-Saharan Africa (SSA) have emerged as leading cancer treatment guidelines in SSA. The objective of this study is to examine the evidence cited in support of the NCCN-SSA guidelines, with a focus on population characteristics and generalizability to SSA. Methods: This meta-research analysis included all studies cited in support of treatment and/or management recommendations in the NCCN-SSA guidelines for the nine most common cancers in SSA. Studies were identified by two independent reviewers; duplicate studies, those lacking individual-level data, and those unrelated to treatment and/or management were excluded. Data on the study type, participant demographics (age, sex, race/ethnicity), and recruitment geography were abstracted from each full-text article. Descriptive analyses were performed using R to characterize the study type (eg, experimental, observational), demographics (mean age, percent female/male, percent by race/ethnicity), and geographic representation overall and by individual cancer type. Results: Overall, 4,589 citations were reviewed and 2,931 (63.9%) studies with individual-level data were included. Of the 2,061 studies reporting geographic information, 50 (2.4%) recruited in SSA; of these, 39 (83.0%) recruited from South Africa. Three studies (0.2%) recruited exclusively in SSA. Most studies (95.3%) recruited exclusively from high- or upper-middle–income countries. Only 29.2% of studies reporting participant race included >10% of Black study participants. Conclusion: Most studies cited in the NCCN-SSA guidelines were conducted in high-income countries outside SSA. A small minority of all study participants were Black. These findings underscore potential limitations in the generalizability of the NCCN-SSA guidelines to SSA and highlight a pressing need to generate and incorporate context-specific data to guide care and inform policy.